We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

31 hedge funds and large institutions have $770K invested in BioXcel Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more call options, than puts

Call options by funds: $17K | Put options by funds: $4K

10.43% more ownership

Funds ownership: 1.09% → 11.52% (+10%)

17% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 12

37% less funds holding

Funds holding: 49 → 31 (-18)

75% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 24

76% less capital invested

Capital invested by funds: $3.22M → $770K (-$2.46M)

Holders
31
Holders Change
-18
Holders Change %
-36.73%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
10
Reduced
12
Closed
24
Calls
$17K
Puts
$4K
Net Calls
+$13K
Net Calls Change
+$18K

Top Buyers

Rank Fund Capital Flow
1
M
Murchinson
Ontario, Canada
+$508K
2
Goldman Sachs
Goldman Sachs
New York
+$92.6K
3
UBS Group
UBS Group
Switzerland
+$82K
4
BPA
Beacon Pointe Advisors
California
+$70.4K
5
VF
Virtu Financial
New York
+$35.9K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.61M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$207K
3
Millennium Management
Millennium Management
New York
-$39.2K
4
Renaissance Technologies
Renaissance Technologies
New York
-$29.1K
5
State Street
State Street
Massachusetts
-$28.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northwestern Mutual Wealth Management
26
Northwestern Mutual Wealth Management
Wisconsin
$43 – – –
Fidelity Investments
27
Fidelity Investments
Massachusetts
$22 +$41 +11 New
FFA
28
Farther Finance Advisors
California
$10 -$4 -1 -17%
FDCDDQ
29
Federation des caisses Desjardins du Quebec
Quebec, Canada
$6 -$15 -4 -57%
DB
30
Danske Bank
Denmark
$6 +$11 +3 New
US Bancorp
31
US Bancorp
Minnesota
$2 -$4 -1 -50%
AC
32
Armistice Capital
New York
– -$1.61M -269,688 Closed
Millennium Management
33
Millennium Management
New York
– -$39.2K -6,561 Closed
Renaissance Technologies
34
Renaissance Technologies
New York
– -$29.1K -4,869 Closed
State Street
35
State Street
Massachusetts
– -$28.8K -4,822 Closed
Northern Trust
36
Northern Trust
Illinois
– -$27.6K -4,619 Closed
Squarepoint
37
Squarepoint
New York
– -$26.9K -4,503 Closed
AZ
38
Alpha Zero
Florida
– -$19.6K -3,272 Closed
AWA
39
Arete Wealth Advisors
Illinois
– -$15K -2,531 Closed
DWM
40
Diversify Wealth Management
Utah
– -$15.1K -2,500 Closed
HWAM
41
Hennion & Walsh Asset Management
New Jersey
– -$14.7K -2,461 Closed
Cambridge Investment Research Advisors
42
Cambridge Investment Research Advisors
Iowa
– -$14K -2,378 Closed
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
– -$12.9K -2,158 Closed
HF
44
HRT Financial
New York
– -$9K -1,594 Closed
Jane Street
45
Jane Street
New York
– -$8.73K -1,459 Closed
TSS
46
Two Sigma Securities
New York
– -$6.47K -1,082 Closed
PAS
47
Point72 Asia (Singapore)
Singapore
– -$5.96K -996 Closed
LPL Financial
48
LPL Financial
California
– -$5.44K -909 Closed
EGM
49
Engineers Gate Manager
New York
– -$4.48K -749 Closed
DC
50
Davenport & Co
Virginia
– -$4.42K -738 Closed
1
2
3

BTAI Hedge Fund Activity: Q1 2025 in Review

31 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2025, worth a combined $770K — down 76% from $3.22M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of BTAI and 6 opened new positions — a net loss of 18 holders — while 12 trimmed existing stakes and 10 added.

The largest buyer was Murchinson, opening a new position worth an estimated $508K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.61M sold.

  • 31 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2025, down from 49 in Q4 2024.
  • Funds reported $770K of BioXcel Therapeutics stock for Q1 2025, down 76% quarter-over-quarter.
  • 6 funds opened new BioXcel Therapeutics positions in Q1 2025 and 24 closed out, a net change of -18 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2025 was Murchinson, an estimated $508K added.
  • The largest BioXcel Therapeutics seller in Q1 2025 was Armistice Capital, an estimated $1.61M sold.

Based on aggregated 13F filings for Q1 2025.